Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.


Pharmaceutical Technology
Volume 32, Issue 1


Table III: Formulation of tablets and Y60, Y300, and t80 of preliminary batches.
The flow properties and compressibility of the dried mucilage, including bulk and tapped density, Carr's index, Hausner ratio, and the angle of repose were assessed and compared with those of guar gum and ispaghula husk (see Table II). The angle of repose of a powder provides an insight into the magnitude of the cohesiveness of the powder and hence, its flowability. Mildly cohesive powders have angles of repose between 40° and 60° when measured by standard methods. Dried mucilage has an angle of repose of 27.83°. Guar gum and ispaghula husk have an angle of repose of 42.27°and 38.79°, respectively. From these results, the authors infer that the dried mucilage powder was less cohesive and had superior flow property. The Hausner ratio previews the degree of densification that could occur during tableting: the higher the ratio, the greater the propensity of the powder to densify. This phenomenon may produce tablets that lack uniformity of weight and content. The dried mucilage has excellent flow properties compared with those of guar gum and ispaghula husk. Dried mucilage, therefore, has flow properties suitable for use in a direct-compression formulation.


Table IV: Formulation and dissolution characteristics of batches in a 32 full factorial design.
The average crushing strength of the prepared tablets was 4.8 kg/cm2 , a value which shows good strength. The friability was < 1% (i.e., between 0.75 and 0.91%). Tablets prepared from dried-powdered mucilage that passed the standard for uniformity in weight indicate homogenous drug content. These results show that tablets prepared from dried-powdered mucilage can be used as a directly compressible vehicle because of good hardness, low friability, and tablet-weight uniformity.

Table III shows the composition of the preliminary batches (L1 to L3) and the results of their dissolution studies. Table IV shows the composition of the nine batches of the factorial design and the results of their dissolution studies. When the dissolution study of the preliminary batches was performed, the complete drug release was obtained within 9, 10, and 11 h with different proportions of mucilage and 100 mg of diclofenac sodium (see Table III). The authors concluded that mucilage is suitable as a sustained-release matrixing agent for a diclofenac sodium tablet. Four criteria were established for the desired drug-release profile:

  • A release of 20–25% of the drug within the first hour.
  • Drug release after 5 h was 40% < Y300 < 60%
  • Prolonged drug release of the remaining drug followed during 12 h, preferably at a relatively constant rate
  • The time to release 80% of the drug was 490 < t80 < 590 min.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here